Head to Head Comparison: CRISPR Therapeutics (NASDAQ:CRSP) & AbbVie (NYSE:ABBV)

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) and AbbVie (NYSE:ABBV – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations.

Insider & Institutional Ownership

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 0.1% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for CRISPR Therapeutics and AbbVie, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CRISPR Therapeutics 1 6 8 2 2.65
AbbVie 0 6 22 1 2.83

CRISPR Therapeutics currently has a consensus target price of $72.93, indicating a potential upside of 80.65%. AbbVie has a consensus target price of $297.85, indicating a potential upside of 1.24%. Given CRISPR Therapeutics’ higher probable upside, equities research analysts clearly believe CRISPR Therapeutics is more favorable than AbbVie.

Profitability

This table compares CRISPR Therapeutics and AbbVie’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CRISPR Therapeutics -1,812.07% -25.59% -17.89%
AbbVie 15.67% -450.55% 16.50%

Valuation & Earnings

This table compares CRISPR Therapeutics and AbbVie”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CRISPR Therapeutics $3.51 million 1,115.64 -$581.60 million ($4.74) -8.52
AbbVie $66.01 billion 7.88 $4.23 billion $5.81 50.63

AbbVie has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

CRISPR Therapeutics has a beta of 1.92, suggesting that its stock price is 92% more volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.2, suggesting that its stock price is 80% less volatile than the S&P 500.

Summary

AbbVie beats CRISPR Therapeutics on 8 of the 14 factors compared between the two stocks.

About CRISPR Therapeutics

(Get Free Report)

CRISPR Therapeutics AG is a biotechnology company focused on developing gene-based medicines using CRISPR/Cas9, a gene-editing technology that can make targeted changes to DNA. Founded in 2013, the company is headquartered in Zug, Switzerland, and maintains U.S. operations in Cambridge, Massachusetts. Its lead product, Casgevy (exa-cel), was developed with Vertex Pharmaceuticals for people with sickle cell disease and transfusion-dependent beta thalassemia. It was the first therapy based on CRISPR gene editing to receive regulatory approval.

About AbbVie

(Get Free Report)

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.